Telmisartan

MUMBAI, Dec 16 - German drugmaker Boehringer Ingelheim has started discussions with India's Cipla for a drug supply agreement, the Economic Times said, citing two unidentified persons familiar with the matter._____HIGHLIGHTS OF PRESCRIBING INFORMATION-----DOSAGE FORMS AND STRENGTHS-----These highlights do not include all the information needed to use ...The electronic Medicines Compendium contains information about UK licensed medicines.Is Cresar superior to Losacar? My friend, a hypertensive and a patient of tachycardia VCP, is on Amlodac AT twice and Losacar H twice. As he had postural hypotension ...

Do not use this medication without telling your doctor if you are pregnant. Telmisartan may cause injury and even death to the unborn baby if you take it during the second and third ...Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free ...Telmisartan-Hydrochlorothiazid side effects, dosage, and drug interactions. All accurate, up-to-date information is written for the consumer by healthcare professionals.The drug can now be used to reduce the risk of MI, stroke, or death from cardiovascular causes in patients 55 years of age or older who are intolerant to ACE inhibitors but at high ...The recently presented results of the VALUE trial have emphasized the critical importance of tight blood pressure control to provide greater protection against cardiovascular ...Buy Generic Micardis pills at http://www.easy.md/.

Medical Simulation Corporation will highlight its full menu of Quality Initiative Programs at the 2009 IHI National Forum, December 7-9, 2009, in Orlando, Florida. MSC is the first simulation company to introduce simulation-based education programs that help healthcare providers bridge the gap between measurement and achievement of publicly reported patient safety and quality initiatives.Telmisartan Shows an Equivalent Effect of Vitamin C in Further Improving Endothelial Dysfunction After Glycemia Normalization in Type 1 DiabetesHyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 .

MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction , stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing ...Boehringer Ingelheim announced that the European Commission has approved MICARDIS® for the reduction of cardiovascular morbidity in patients with: I. manifest atherothrombotic cardiovascular disease or, II. type 2 diabetes mellitus with documented target organ damage.MICARDIS® has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme inhibitor.